Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

6 of 6 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 1
3(50.0%)
Phase 2
3(50.0%)
6Total
Phase 1(3)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT02526524Phase 2Completed

Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM

Role: lead

NCT01819272Phase 2Completed

Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks

Role: lead

NCT02291510Phase 1Completed

Assessing the PK of Met DR, Met IR, and Met XR in Healthy Subjects

Role: lead

NCT01804842Phase 1Completed

Assessing the Effect of Met DR on Plasma Glucose and PK in Subjects With T2DM

Role: lead

NCT01677299Phase 1Completed

Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM

Role: lead

NCT01658514Phase 2Completed

Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction

Role: lead

All 6 trials loaded